Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex

Pharmaceutical Research

Volumn 21, Issue 5, 2004, Pages 891-894

  Jerremalm, Elin ^a   Hedeland, Mikael ^b   Wallin, Inger ^a   Bondesson, Ulf ^b,c   Ehrsson, Hans ^a,d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL VETERINARY INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biotransformation; HT 29; Pt(dach)Cl2

Indexed keywords

AMMONIA; CHLORIDE; METHANOL; OXALIPLATIN;

ANALYTICAL EQUIPMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG DEGRADATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; INSTRUMENTATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CHLORIDES; CHROMATOGRAPHY, LIQUID; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HT29 CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TUMOR STEM CELL ASSAY;

EID: 3543021553     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000026444.67883.83     Document Type: Article

References (10)

1. S. Mani, M. A. Graham, D. B. Bregman, P. Ivy, and S. G. Chaney. Oxaliplatin: a review of evolving concepts. Cancer Invest. 20:246-263 (2002).
2. H. Ehrsson, I. Wallin, and J. Yachnin. Pharmacokinetics of oxaliplatin in humans. Med. Oncol. 19:261-265 (2002).
3. M. A. Graham, G. F. Lockwood, D. Greenslade, S. Brienza, M. Bayssas, and E. Gamelin. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin. Cancer Res. 6:1205-1218 (2000).
4. P. Allain, O. Heudi, A. Cailleux, A. Le Bouil, F. Larra, M. Boisdron-Celle, and E. Gamelin. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab. Dispos. 28:1379-1384 (2000).
5. F. R. Luo, S. D. Wyrick, and S. G. Chaney. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol. Res. 10:595-603 (1998).
6. P. Videhult, J. Yachnin, E. Jerremalm, R. Lewensohn, and H. Ehrsson. Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin. Cancer Lett. 180:191-194 (2002).
7. J. L. Butour, A. M. Mazard, and J. P. Macquet. Kinetics of the reaction of cis-platinum compounds with DNA in vitro. Biochem. Biophys. Res. Commun. 133:347-353 (1985).
8. 2(CBDCA-O)(5′-GMP-N7)] in solution. Inorg. Chem. 32:1333-1340 (1993).
9. S. S. Shord, S. A. Bernard, C. Lindley, A. Blodgett, V. Mehta, M. A. Churchel, M. Poole, S. L. Pescatore, F. R. Luo, and S. G. Chaney. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. Anticancer Res. 22:2301-2310 (2002).
10. G. Siebert. The biochemical environment of the mammalian nucleus. Sub-Cell. Biochem. 1:277-292 (1972).